Skip to main content
Top

05-04-2024 | Acute Kidney Injury | Guidelines

APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure

Authors: Rakhi Maiwall, Satender Pal Singh, Paolo Angeli, Richard Moreau, Aleksander Krag, Virender Singh, Ashwani K. Singal, S. S. Tan, Puneet Puri, Mamun Mahtab, George Lau, Qin Ning, Manoj Kumar Sharma, P. N. Rao, Dharmesh Kapoor, Subhash Gupta, Ajay Duseja, Manav Wadhawan, Dinesh Jothimani, Sanjiv Saigal, Sunil Taneja, Akash Shukla, Pankaj Puri, Deepak Govil, Gaurav Pandey, Kaushal Madan, C. E. Eapen, Jaya Benjamin, Ashok Chowdhury, Shweta Singh, Vaishali Salao, Jin Mo Yang, Saeed Hamid, Shalimar, Sanjiv Jasuja, Anand V. Kulkarni, Madund A. Niriella, Harsh Vardhan Tevethia, Vinod Arora, R. P. Mathur, Akash Roy, Ankur Jindal, Neeraj Saraf, Nipun Verma, Arka De, Narendra S. Choudhary, Rohit Mehtani, Phool Chand, Omkar Rudra, Shiv Kumar Sarin

Published in: Hepatology International

Login to get access

Abstract

Acute-on-chronic liver failure (ACLF) is a syndrome that is characterized by the rapid development of organ failures predisposing these patients to a high risk of short-term early death. The main causes of organ failure in these patients are bacterial infections and systemic inflammation, both of which can be severe. For the majority of these patients, a prompt liver transplant is still the only effective course of treatment. Kidneys are one of the most frequent extrahepatic organs that are affected in patients with ACLF, since acute kidney injury (AKI) is reported in 22.8–34% of patients with ACLF. Approach and management of kidney injury could improve overall outcomes in these patients. Importantly, patients with ACLF more frequently have stage 3 AKI with a low rate of response to the current treatment modalities. The objective of the present position paper is to critically review and analyze the published data on AKI in ACLF, evolve a consensus, and provide recommendations for early diagnosis, pathophysiology, prevention, and management of AKI in patients with ACLF. In the absence of direct evidence, we propose expert opinions for guidance in managing AKI in this very challenging group of patients and focus on areas of future research. This consensus will be of major importance to all hepatologists, liver transplant surgeons, and intensivists across the globe.
Literature
1.
go back to reference Sarin SK, Chandan K, Zaigham A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2014;8:453–471PubMedCrossRef Sarin SK, Chandan K, Zaigham A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2014;8:453–471PubMedCrossRef
2.
go back to reference Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3(269):282 Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3(269):282
3.
go back to reference Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov, 13(6), pp. 826–828]. Hepatol Int. 2019;13:353–390PubMedCrossRef Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov, 13(6), pp. 826–828]. Hepatol Int. 2019;13:353–390PubMedCrossRef
4.
go back to reference Piano S, Tonon M, Vettore E, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–1184PubMedCrossRef Piano S, Tonon M, Vettore E, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–1184PubMedCrossRef
6.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79:461–491CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79:461–491CrossRef
7.
go back to reference Trebicka J, Fernandez J, Papp M, PREDICT STUDY group of the EASL-CLIF CONSORTIUM, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2021;74:1097–1108PubMedCrossRef Trebicka J, Fernandez J, Papp M, PREDICT STUDY group of the EASL-CLIF CONSORTIUM, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2021;74:1097–1108PubMedCrossRef
8.
go back to reference Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10PubMedCrossRef Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10PubMedCrossRef
9.
go back to reference Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114:929–937PubMedCrossRef Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114:929–937PubMedCrossRef
10.
go back to reference Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int. 2016;10:245–257PubMedCrossRef Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int. 2016;10:245–257PubMedCrossRef
11.
go back to reference Maiwall R, Kumar S, Chandel SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int. 2015;9:627–639PubMedCrossRef Maiwall R, Kumar S, Chandel SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int. 2015;9:627–639PubMedCrossRef
12.
go back to reference Maiwall R, Sarin SK, Kumar S, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int. 2017;37:1497–1507PubMedCrossRef Maiwall R, Sarin SK, Kumar S, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int. 2017;37:1497–1507PubMedCrossRef
13.
go back to reference Maiwall R, Rastogi A, Pasupuleti SSR, et al. Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure. Liver Int. 2022;42:2800–2814PubMedCrossRef Maiwall R, Rastogi A, Pasupuleti SSR, et al. Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure. Liver Int. 2022;42:2800–2814PubMedCrossRef
14.
go back to reference Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;7:811–822CrossRef Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;7:811–822CrossRef
15.
go back to reference Amathieu R, Al-Khafaji A, Sileanu FEF, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66:1592–1600PubMedCrossRef Amathieu R, Al-Khafaji A, Sileanu FEF, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66:1592–1600PubMedCrossRef
16.
go back to reference Bianchi NA, Stavart LL, Altarelli M, et al. Association of oliguria with acute kidney injury diagnosis, severity assessment, and mortality among patients with critical illness. JAMA Netw Open. 2021;1(4): e2133094CrossRef Bianchi NA, Stavart LL, Altarelli M, et al. Association of oliguria with acute kidney injury diagnosis, severity assessment, and mortality among patients with critical illness. JAMA Netw Open. 2021;1(4): e2133094CrossRef
17.
go back to reference Maiwall R, Pasupuleti SSR, Chandel SS, et al. Co-orchestration of acute kidney injury and non-kidney organ failures in critically ill patients with cirrhosis. Liver Int. 2021;41:1358–1369PubMedCrossRef Maiwall R, Pasupuleti SSR, Chandel SS, et al. Co-orchestration of acute kidney injury and non-kidney organ failures in critically ill patients with cirrhosis. Liver Int. 2021;41:1358–1369PubMedCrossRef
18.
go back to reference Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257PubMedCrossRef Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257PubMedCrossRef
20.
go back to reference Choudhury A, Kumar M, Sharma BC, APASL ACLF working party, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study. J Gastroenterol Hepatol. 2017;32:1989–1997PubMedCrossRef Choudhury A, Kumar M, Sharma BC, APASL ACLF working party, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study. J Gastroenterol Hepatol. 2017;32:1989–1997PubMedCrossRef
21.
go back to reference Clària J, Stauber RE, Coenraad MJ, CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–1264PubMedCrossRef Clària J, Stauber RE, Coenraad MJ, CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–1264PubMedCrossRef
22.
go back to reference Arroyo V, Angeli P, Moreau R, Investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif), et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670–685PubMedCrossRef Arroyo V, Angeli P, Moreau R, Investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif), et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670–685PubMedCrossRef
23.
go back to reference Moreau R, Clària J, Aguilar F, CANONIC Study Investigators of the EASL Clif Consortium; Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701PubMedCrossRef Moreau R, Clària J, Aguilar F, CANONIC Study Investigators of the EASL Clif Consortium; Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701PubMedCrossRef
24.
go back to reference Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol. 2021;74:1117–1131PubMedCrossRef Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol. 2021;74:1117–1131PubMedCrossRef
25.
go back to reference Clària J, Moreau R, Fenaille F, CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019;69:1686–1701PubMedCrossRef Clària J, Moreau R, Fenaille F, CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019;69:1686–1701PubMedCrossRef
26.
go back to reference van Slambrouck CM, Salem F, Meehan SM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192–197PubMedCrossRef van Slambrouck CM, Salem F, Meehan SM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192–197PubMedCrossRef
27.
28.
go back to reference Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65:2461–2483PubMedCrossRef Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65:2461–2483PubMedCrossRef
29.
go back to reference Lee J, Azzaroli F, Wang L, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology. 2001;121:1473–1484PubMedCrossRef Lee J, Azzaroli F, Wang L, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology. 2001;121:1473–1484PubMedCrossRef
30.
go back to reference Krones E, Eller K, Pollheimer MJ, et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol. 2017;67:110–119PubMedCrossRef Krones E, Eller K, Pollheimer MJ, et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol. 2017;67:110–119PubMedCrossRef
31.
go back to reference Bräsen JH, Mederacke YS, Schmitz J, et al. Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology. 2019;69:2107–2119PubMedCrossRef Bräsen JH, Mederacke YS, Schmitz J, et al. Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology. 2019;69:2107–2119PubMedCrossRef
32.
go back to reference Nayak SL, Kumar M, Bihari C, et al. Bile cast nephropathy in patients with acute kidney injury due to hepatorenal syndrome: a post-mortem kidney biopsy study. J Clin Transl Hepatol. 2017;28(5):92–100 Nayak SL, Kumar M, Bihari C, et al. Bile cast nephropathy in patients with acute kidney injury due to hepatorenal syndrome: a post-mortem kidney biopsy study. J Clin Transl Hepatol. 2017;28(5):92–100
38.
go back to reference Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257PubMedCrossRef Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257PubMedCrossRef
39.
go back to reference Patidar KR, Naved MA, Grama A, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022;77:108–115PubMedCrossRef Patidar KR, Naved MA, Grama A, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022;77:108–115PubMedCrossRef
40.
go back to reference Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol. 2021;74:578–583PubMedCrossRef Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol. 2021;74:578–583PubMedCrossRef
41.
go back to reference Maiwall R, Kumar A, Bhardwaj A, et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver Int. 2018;38(4):654–664PubMedCrossRef Maiwall R, Kumar A, Bhardwaj A, et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver Int. 2018;38(4):654–664PubMedCrossRef
42.
go back to reference Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology. 2020;71:1009–1022PubMedCrossRef Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology. 2020;71:1009–1022PubMedCrossRef
43.
go back to reference Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol. 2020;72:1132–1139PubMedCrossRef Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol. 2020;72:1132–1139PubMedCrossRef
44.
45.
go back to reference Yazawa M, Maliakkal B, Nair S, et al. Longitudinal renal function in liver transplant recipients with acute-on-chronic liver failure. Clin Transl Gastroenterol. 2020;11: e00185PubMedPubMedCentralCrossRef Yazawa M, Maliakkal B, Nair S, et al. Longitudinal renal function in liver transplant recipients with acute-on-chronic liver failure. Clin Transl Gastroenterol. 2020;11: e00185PubMedPubMedCentralCrossRef
46.
go back to reference Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27:31–37PubMedCrossRef Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27:31–37PubMedCrossRef
47.
go back to reference Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44:457–464PubMedCrossRef Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44:457–464PubMedCrossRef
48.
go back to reference Navis G, Faber HJ, de Zeeuw D, et al. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 1996;15:200–211PubMedCrossRef Navis G, Faber HJ, de Zeeuw D, et al. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 1996;15:200–211PubMedCrossRef
49.
go back to reference Guevara M, Fernández-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646–651PubMedCrossRef Guevara M, Fernández-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646–651PubMedCrossRef
50.
go back to reference Campion D, Ponzo P, Risso A, et al. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis [published online ahead of print, 2023 Oct 19]. J Hepatol. 2023;S0168-8278(23)05176–0. Campion D, Ponzo P, Risso A, et al. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis [published online ahead of print, 2023 Oct 19]. J Hepatol. 2023;S0168-8278(23)05176–0.
51.
go back to reference Zang H, Liu F, Liu H, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int. 2016;10:807–818PubMedCrossRef Zang H, Liu F, Liu H, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int. 2016;10:807–818PubMedCrossRef
52.
go back to reference Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology. 2020;72:1043–1055PubMedCrossRef Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology. 2020;72:1043–1055PubMedCrossRef
53.
go back to reference Palsson R, Waikar SS. Renal functional reserve revisited. Adv Chronic Kidney Dis. 2018;25(3):e1–e8PubMedCrossRef Palsson R, Waikar SS. Renal functional reserve revisited. Adv Chronic Kidney Dis. 2018;25(3):e1–e8PubMedCrossRef
54.
go back to reference Hsu WF, Yu SH, Lin JT, et al. Renal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with liver cirrhosis: a nationwide cohort study. Gastroenterol Res Pract. 2019;10(2019):1743290 Hsu WF, Yu SH, Lin JT, et al. Renal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with liver cirrhosis: a nationwide cohort study. Gastroenterol Res Pract. 2019;10(2019):1743290
55.
go back to reference Tergast TL, Griemsmann M, Wedemeyer H, Cornberg M, Maasoumy B. Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis. Sci Rep. 2023;13(1):17486PubMedPubMedCentralCrossRef Tergast TL, Griemsmann M, Wedemeyer H, Cornberg M, Maasoumy B. Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis. Sci Rep. 2023;13(1):17486PubMedPubMedCentralCrossRef
56.
go back to reference Sersté T, Njimi H, Degré D, et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35(8):1974–1982PubMedCrossRef Sersté T, Njimi H, Degré D, et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35(8):1974–1982PubMedCrossRef
57.
go back to reference Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–587PubMedCrossRef Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–587PubMedCrossRef
58.
go back to reference Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63(3):593–600PubMedCrossRef Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63(3):593–600PubMedCrossRef
60.
go back to reference Vural A, Koçyiğit İ, Şan F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: a randomized trial. Perit Dial Int. 2018;38(1):57–62PubMedCrossRef Vural A, Koçyiğit İ, Şan F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: a randomized trial. Perit Dial Int. 2018;38(1):57–62PubMedCrossRef
61.
go back to reference Kan W-C, Chen Y-C, Wu V-C, Shiao C-C. Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. Int J Mol Sci. 2022;23(4):2052PubMedPubMedCentralCrossRef Kan W-C, Chen Y-C, Wu V-C, Shiao C-C. Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. Int J Mol Sci. 2022;23(4):2052PubMedPubMedCentralCrossRef
62.
go back to reference Velez JCQ, Obadan NO, Kaushal A, et al. Vancomycin-associated acute kidney injury with a steep rise in serum creatinine. Nephron. 2018;139:131–142PubMedCrossRef Velez JCQ, Obadan NO, Kaushal A, et al. Vancomycin-associated acute kidney injury with a steep rise in serum creatinine. Nephron. 2018;139:131–142PubMedCrossRef
65.
go back to reference Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236–244PubMedCrossRef Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236–244PubMedCrossRef
66.
go back to reference Wan ZH, Wang JJ, You SL, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;28(19):9432–9438CrossRef Wan ZH, Wang JJ, You SL, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;28(19):9432–9438CrossRef
67.
go back to reference Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188–e198PubMedCrossRef Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188–e198PubMedCrossRef
68.
go back to reference Jha P, Jha AK, Dayal VM, et al. Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure. Indian J Gastroenterol. 2021;40:563–571PubMedCrossRef Jha P, Jha AK, Dayal VM, et al. Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure. Indian J Gastroenterol. 2021;40:563–571PubMedCrossRef
70.
go back to reference Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017;66:1232–1241PubMedCrossRef Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017;66:1232–1241PubMedCrossRef
71.
go back to reference Lu J, Lin L, Ye C, et al. Serum NGAL is superior to cystatin c in predicting the prognosis of acute-on-chronic liver failure. Ann Hepatol. 2019;18(1):155–164PubMedCrossRef Lu J, Lin L, Ye C, et al. Serum NGAL is superior to cystatin c in predicting the prognosis of acute-on-chronic liver failure. Ann Hepatol. 2019;18(1):155–164PubMedCrossRef
72.
go back to reference Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24(21):2300–2310PubMedPubMedCentralCrossRef Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24(21):2300–2310PubMedPubMedCentralCrossRef
74.
76.
go back to reference Ariza X, Graupera I, Coll M, CANONIC Investigators, EASL CLIF Consortium, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65:57–65PubMedCrossRef Ariza X, Graupera I, Coll M, CANONIC Investigators, EASL CLIF Consortium, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65:57–65PubMedCrossRef
85.
go back to reference Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018;8(1):7962PubMedPubMedCentralCrossRef Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018;8(1):7962PubMedPubMedCentralCrossRef
87.
go back to reference Patidar KR, Xu C, Shamseddeen H, et al. Development and validation of a model to predict acute kidney injury in hospitalized patients with cirrhosis. Clin Transl Gastroenterol. 2019;10: e00075PubMedPubMedCentralCrossRef Patidar KR, Xu C, Shamseddeen H, et al. Development and validation of a model to predict acute kidney injury in hospitalized patients with cirrhosis. Clin Transl Gastroenterol. 2019;10: e00075PubMedPubMedCentralCrossRef
88.
go back to reference Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of n-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;5(8): 724224CrossRef Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of n-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;5(8): 724224CrossRef
89.
go back to reference Kulkarni AV, Anand L, Vyas AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial. J Gastroenterol Hepatol. 2021;36:1953–1961PubMedCrossRef Kulkarni AV, Anand L, Vyas AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial. J Gastroenterol Hepatol. 2021;36:1953–1961PubMedCrossRef
90.
go back to reference Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholichepatitis–a randomised clinical trial. J Hepatol. 2006;44:784–790PubMedCrossRef Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholichepatitis–a randomised clinical trial. J Hepatol. 2006;44:784–790PubMedCrossRef
91.
go back to reference Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholichepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117–1122PubMedCrossRef Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholichepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117–1122PubMedCrossRef
92.
go back to reference Nguyen-Khac E, Thevenot T, Piquet MA, AAH-NAC Study Group, et al. Glucocorticoids plus N-acetylcysteine in severe alcohol-related hepatitis. N Engl J Med. 2011;365:1781–1789PubMedCrossRef Nguyen-Khac E, Thevenot T, Piquet MA, AAH-NAC Study Group, et al. Glucocorticoids plus N-acetylcysteine in severe alcohol-related hepatitis. N Engl J Med. 2011;365:1781–1789PubMedCrossRef
94.
go back to reference Szabo G, Mitchell M, McClain CJ, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022;76:1058–1068PubMedCrossRef Szabo G, Mitchell M, McClain CJ, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022;76:1058–1068PubMedCrossRef
95.
go back to reference Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018;16:1650-1656.e2PubMedCrossRef Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018;16:1650-1656.e2PubMedCrossRef
96.
go back to reference Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure [published correction appears in Gastroenterology. 2013 Sep;145(3):695. Dosage error in article text]. Gastroenterology. 2009;137(3):856-864.e1PubMedCrossRef Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure [published correction appears in Gastroenterology. 2013 Sep;145(3):695. Dosage error in article text]. Gastroenterology. 2009;137(3):856-864.e1PubMedCrossRef
97.
go back to reference Walayat S, Shoaib H, Asghar M, Kim M, Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235–240PubMedPubMedCentral Walayat S, Shoaib H, Asghar M, Kim M, Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235–240PubMedPubMedCentral
98.
go back to reference Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of N-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;8: 724224 (Published 2021 Aug 5)PubMedPubMedCentralCrossRef Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of N-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;8: 724224 (Published 2021 Aug 5)PubMedPubMedCentralCrossRef
99.
go back to reference Bai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023;5(8): 100785 (Published 2023 May 5)PubMedPubMedCentralCrossRef Bai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023;5(8): 100785 (Published 2023 May 5)PubMedPubMedCentralCrossRef
100.
go back to reference Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409PubMedCrossRef Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409PubMedCrossRef
101.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417CrossRef
102.
go back to reference Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019;157:149–162PubMedCrossRef Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019;157:149–162PubMedCrossRef
103.
go back to reference Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–840PubMedCrossRef Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–840PubMedCrossRef
104.
go back to reference Engelmann C, Herber A, Franke A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study). J Hepatol. 2021;75:1346–1354PubMedCrossRef Engelmann C, Herber A, Franke A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study). J Hepatol. 2021;75:1346–1354PubMedCrossRef
105.
go back to reference Engelmann C, Habtesion A, Hassan M, et al. Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol. 2022;77:1325–1338PubMedCrossRef Engelmann C, Habtesion A, Hassan M, et al. Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol. 2022;77:1325–1338PubMedCrossRef
106.
go back to reference Martin-Mateos R, González-Alonso R, Álvarez-Díaz N, et al. Granulocyte-colony stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis of randomized controlled trials. Gastroenterol Hepatol. 2023;46:350–359PubMedCrossRef Martin-Mateos R, González-Alonso R, Álvarez-Díaz N, et al. Granulocyte-colony stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis of randomized controlled trials. Gastroenterol Hepatol. 2023;46:350–359PubMedCrossRef
107.
go back to reference Moreau R, Rautou PE. G-CSF therapy for severe alcohol-related hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol. 2014;109:1424–1426PubMedCrossRef Moreau R, Rautou PE. G-CSF therapy for severe alcohol-related hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol. 2014;109:1424–1426PubMedCrossRef
108.
go back to reference Engelmann C, Martino VD, Kerbert AJC, et al. The current status of granulocyte-colony stimulating factor to treat acute-on-chronic liver failure. Semin Liver Dis. 2021;41:298–307PubMedCrossRef Engelmann C, Martino VD, Kerbert AJC, et al. The current status of granulocyte-colony stimulating factor to treat acute-on-chronic liver failure. Semin Liver Dis. 2021;41:298–307PubMedCrossRef
109.
go back to reference Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;21(19):1104–1110CrossRef Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;21(19):1104–1110CrossRef
110.
go back to reference Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:505-512.e1PubMedCrossRef Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:505-512.e1PubMedCrossRef
111.
go back to reference Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int. 2014 ;34:505–13. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int. 2014 ;34:505–13.
112.
go back to reference Marot A, Singal AK, Moreno C, et al. A systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020;18(2): 100139CrossRef Marot A, Singal AK, Moreno C, et al. A systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020;18(2): 100139CrossRef
113.
go back to reference Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholichepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109:1417–1423PubMedCrossRef Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholichepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109:1417–1423PubMedCrossRef
114.
go back to reference Mookerjee RP, Pavesi M, Thomsen KL, CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–582PubMedCrossRef Mookerjee RP, Pavesi M, Thomsen KL, CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–582PubMedCrossRef
115.
go back to reference Kumar M, Kainth S, Choudhury A, et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2019;13:800–813PubMedCrossRef Kumar M, Kainth S, Choudhury A, et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2019;13:800–813PubMedCrossRef
116.
go back to reference Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol. 2022;1(117):607–616CrossRef Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol. 2022;1(117):607–616CrossRef
119.
go back to reference Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012;81:819–825PubMedCrossRef Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012;81:819–825PubMedCrossRef
120.
121.
go back to reference Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;22(8):66CrossRef Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;22(8):66CrossRef
122.
go back to reference Hoste EA, Maitland K, Brudney CS, ADQI XII Investigators Group, et al. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113:740–747PubMedCrossRef Hoste EA, Maitland K, Brudney CS, ADQI XII Investigators Group, et al. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113:740–747PubMedCrossRef
124.
go back to reference Grissom CK, Hirshberg EL, Dickerson JB, National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med. 2015;43:288–295PubMedPubMedCentralCrossRef Grissom CK, Hirshberg EL, Dickerson JB, National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med. 2015;43:288–295PubMedPubMedCentralCrossRef
125.
go back to reference Philips CA, Maiwall R, Sharma MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int. 2021;15:983–994PubMedCrossRef Philips CA, Maiwall R, Sharma MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int. 2021;15:983–994PubMedCrossRef
126.
go back to reference Finfer S, Bellomo R, Boyce N, SAFE Study Investigators, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256PubMedCrossRef Finfer S, Bellomo R, Boyce N, SAFE Study Investigators, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256PubMedCrossRef
127.
go back to reference Maiwall R, Kumar A, Pasupuleti SSR, et al. A randomized-controlled trial comparing 20% albumin to PlasmaLyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol. 2022;77:670–682PubMedCrossRef Maiwall R, Kumar A, Pasupuleti SSR, et al. A randomized-controlled trial comparing 20% albumin to PlasmaLyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol. 2022;77:670–682PubMedCrossRef
128.
go back to reference Sen A, Keener CM, Sileanu FE, et al. Chloride content of fluids used for large-volume resuscitation is associated with reduced survival. Crit Care Med. 2016;45:e146–e153CrossRef Sen A, Keener CM, Sileanu FE, et al. Chloride content of fluids used for large-volume resuscitation is associated with reduced survival. Crit Care Med. 2016;45:e146–e153CrossRef
130.
go back to reference Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA. 2015;314:1701–1710PubMedCrossRef Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA. 2015;314:1701–1710PubMedCrossRef
131.
go back to reference Reddy SK, Bailey MJ, Beasley RW, et al. A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. Crit Care Resusc. 2014;16(4):274–279PubMed Reddy SK, Bailey MJ, Beasley RW, et al. A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. Crit Care Resusc. 2014;16(4):274–279PubMed
133.
go back to reference Finfer S, Micallef S, Hammond N, PLUS Study Investigators and the Australian New Zealand Intensive Care Society Clinical Trials Group, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022;386:815–826PubMedCrossRef Finfer S, Micallef S, Hammond N, PLUS Study Investigators and the Australian New Zealand Intensive Care Society Clinical Trials Group, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022;386:815–826PubMedCrossRef
134.
go back to reference Beaubien-Souligny W, Trott T, Neyra JA. How to determine fluid management goals during continuous kidney replacement therapy in patients with AKI: focus on POCUS. Kidney360. 2022;3:1795–1806PubMedPubMedCentralCrossRef Beaubien-Souligny W, Trott T, Neyra JA. How to determine fluid management goals during continuous kidney replacement therapy in patients with AKI: focus on POCUS. Kidney360. 2022;3:1795–1806PubMedPubMedCentralCrossRef
136.
137.
go back to reference Nadeau-Fredette AC, Bouchard J. Fluid management and use of diuretics in acute kidney injury. Adv Chronic Kidney Dis. 2013;20:45–55PubMedCrossRef Nadeau-Fredette AC, Bouchard J. Fluid management and use of diuretics in acute kidney injury. Adv Chronic Kidney Dis. 2013;20:45–55PubMedCrossRef
138.
go back to reference Zhou S, Zeng Z, Wei H, et al. Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database. Ann Intensive Care. 2021;11:42PubMedPubMedCentralCrossRef Zhou S, Zeng Z, Wei H, et al. Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database. Ann Intensive Care. 2021;11:42PubMedPubMedCentralCrossRef
142.
go back to reference KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138 KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138
143.
go back to reference Hjortrup PB, Haase N, Bundgaard H, et al. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med. 2016;42:1695–1705PubMedCrossRef Hjortrup PB, Haase N, Bundgaard H, et al. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med. 2016;42:1695–1705PubMedCrossRef
144.
go back to reference China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;4(384):808–817CrossRef China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;4(384):808–817CrossRef
146.
go back to reference Wong F, Pappas SC, Curry MP, CONFIRM Study Investigators, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;4(384):818–828CrossRef Wong F, Pappas SC, Curry MP, CONFIRM Study Investigators, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;4(384):818–828CrossRef
147.
go back to reference Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71:600–610PubMedCrossRef Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71:600–610PubMedCrossRef
148.
go back to reference Jindal A, Bhadoria AS, Maiwall R, et al. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure. Liver Int. 2016;36:59–67PubMedCrossRef Jindal A, Bhadoria AS, Maiwall R, et al. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure. Liver Int. 2016;36:59–67PubMedCrossRef
149.
go back to reference Massicotte L, Perrault MA, Denault AY, et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation. 2010;89:920–927PubMedCrossRef Massicotte L, Perrault MA, Denault AY, et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation. 2010;89:920–927PubMedCrossRef
150.
go back to reference Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology. 2002;36:1070–1078PubMedCrossRef Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology. 2002;36:1070–1078PubMedCrossRef
151.
go back to reference Piano S, Gambino C, Vettore E, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2021;73:1909–1919PubMedCrossRef Piano S, Gambino C, Vettore E, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2021;73:1909–1919PubMedCrossRef
157.
go back to reference Maiwall R, Rao Pasupuleti SS, Hidam AK, et al. A randomised-controlled trial (TARGET-C) of high vs low target mean arterial pressure in patients with cirrhosis and septic shock. J Hepatol. 2023;79:349–361PubMedCrossRef Maiwall R, Rao Pasupuleti SS, Hidam AK, et al. A randomised-controlled trial (TARGET-C) of high vs low target mean arterial pressure in patients with cirrhosis and septic shock. J Hepatol. 2023;79:349–361PubMedCrossRef
162.
go back to reference Cavallin M, Kamath PS, Merli M, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–574. https://doi.org/10.1002/hep.27709. (Epub 2015 Feb 13 PMID: 25644760)CrossRefPubMed Cavallin M, Kamath PS, Merli M, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–574. https://​doi.​org/​10.​1002/​hep.​27709. (Epub 2015 Feb 13 PMID: 25644760)CrossRefPubMed
167.
go back to reference STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Timing of initiation of renal-replacement therapy in acute kidney injury [published correction appears in N Engl J Med. 2020 Jul 15;:]. N Engl J Med. 2020;383(3):240–251. https://doi.org/10.1056/NEJMoa2000741CrossRef STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Timing of initiation of renal-replacement therapy in acute kidney injury [published correction appears in N Engl J Med. 2020 Jul 15;:]. N Engl J Med. 2020;383(3):240–251. https://​doi.​org/​10.​1056/​NEJMoa2000741CrossRef
168.
go back to reference Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;24–31(315):2190–2199CrossRef Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;24–31(315):2190–2199CrossRef
169.
go back to reference Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–133PubMedCrossRef Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–133PubMedCrossRef
170.
go back to reference Gaudry S, Hajage D, Schortgen F, et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomized clinical trial. Am J Respir Crit Care Med. 2018;1(198):58–66CrossRef Gaudry S, Hajage D, Schortgen F, et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomized clinical trial. Am J Respir Crit Care Med. 2018;1(198):58–66CrossRef
171.
go back to reference Lin WT, Lai CC, Chang SP, Wang JJ. Effects of early dialysis on the outcomes of critically ill patients with acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):18283PubMedPubMedCentralCrossRef Lin WT, Lai CC, Chang SP, Wang JJ. Effects of early dialysis on the outcomes of critically ill patients with acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):18283PubMedPubMedCentralCrossRef
172.
go back to reference Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021;397(10281):1293–1300PubMedCrossRef Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021;397(10281):1293–1300PubMedCrossRef
174.
go back to reference Meersch M, Küllmar M, Schmidt C, et al. Long-term clinical outcomes after early initiation of rrt in critically ill patients with AKI. J Am Soc Nephrol. 2018;29:1011–1019PubMedCrossRef Meersch M, Küllmar M, Schmidt C, et al. Long-term clinical outcomes after early initiation of rrt in critically ill patients with AKI. J Am Soc Nephrol. 2018;29:1011–1019PubMedCrossRef
175.
go back to reference Harvey AK, Burns KEA, McArthur E, et al. Short-and long-term outcomes of sustained low efficiency dialysis vs continuous renal replacement therapy in critically ill patients with acute kidney injury. J Crit Care. 2021;62:76–81PubMedCrossRef Harvey AK, Burns KEA, McArthur E, et al. Short-and long-term outcomes of sustained low efficiency dialysis vs continuous renal replacement therapy in critically ill patients with acute kidney injury. J Crit Care. 2021;62:76–81PubMedCrossRef
176.
go back to reference Tolwani AJ, Wheeler TS, Wille KM. Sustained low-efficiency dialysis. Contrib Nephrol. 2007;156:320–324PubMedCrossRef Tolwani AJ, Wheeler TS, Wille KM. Sustained low-efficiency dialysis. Contrib Nephrol. 2007;156:320–324PubMedCrossRef
177.
178.
go back to reference Macedo E, Claure-Del Granado R, Mehta RL. Effluent volume and dialysis dose in CRRT: time for reappraisal. Nat Rev Nephrol. 2011;8(1):57–60PubMedCrossRef Macedo E, Claure-Del Granado R, Mehta RL. Effluent volume and dialysis dose in CRRT: time for reappraisal. Nat Rev Nephrol. 2011;8(1):57–60PubMedCrossRef
179.
go back to reference Ronco C, Bellomo R. New CRRT systems: impact on dose delivery. Am J Kidney Dis. 1997;30(5 Suppl 4):S15–S19PubMedCrossRef Ronco C, Bellomo R. New CRRT systems: impact on dose delivery. Am J Kidney Dis. 1997;30(5 Suppl 4):S15–S19PubMedCrossRef
180.
go back to reference Warrillow S, Fisher C, Tibballs H, Australasian Management of Acute Liver Failure Investigators (AMALFI), et al. Continuous renal replacement therapy and its impact on hyperammonaemia in acute liver failure. Crit Care Resusc. 2020;22(2):158–165PubMed Warrillow S, Fisher C, Tibballs H, Australasian Management of Acute Liver Failure Investigators (AMALFI), et al. Continuous renal replacement therapy and its impact on hyperammonaemia in acute liver failure. Crit Care Resusc. 2020;22(2):158–165PubMed
181.
go back to reference Fayad AI, Buamscha DG, Ciapponi A. Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database Syst Rev. 2016;10:CD010613PubMed Fayad AI, Buamscha DG, Ciapponi A. Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database Syst Rev. 2016;10:CD010613PubMed
182.
go back to reference Cardoso FS, Gottfried M, Tujios S, US Acute Liver Failure Study Group, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2018;67:711–720PubMedCrossRef Cardoso FS, Gottfried M, Tujios S, US Acute Liver Failure Study Group, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2018;67:711–720PubMedCrossRef
183.
go back to reference Fisher C, Baldwin I, Fealy N, et al. Ammonia clearance with different continuous renal replacement therapy techniques in patients with liver failure. Blood Purif. 2022;51:840–846PubMedCrossRef Fisher C, Baldwin I, Fealy N, et al. Ammonia clearance with different continuous renal replacement therapy techniques in patients with liver failure. Blood Purif. 2022;51:840–846PubMedCrossRef
184.
go back to reference Saraiva IE, Ortiz-Soriano VM, Mei X, et al. Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: a retrospective cohort study. Clin Nephrol. 2020;93:187–194PubMedCrossRef Saraiva IE, Ortiz-Soriano VM, Mei X, et al. Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: a retrospective cohort study. Clin Nephrol. 2020;93:187–194PubMedCrossRef
185.
go back to reference Schultheis C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;22(16):R162CrossRef Schultheis C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;22(16):R162CrossRef
186.
go back to reference Patel S, Wendon J. Regional citrate anticoagulation in patients with liver failure—time for a rethink? Crit Care. 2012;17(16):153CrossRef Patel S, Wendon J. Regional citrate anticoagulation in patients with liver failure—time for a rethink? Crit Care. 2012;17(16):153CrossRef
187.
go back to reference Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019;23(1):22PubMedPubMedCentralCrossRef Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019;23(1):22PubMedPubMedCentralCrossRef
188.
go back to reference Staufer K, Roedl K, Kivaranovic D, et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int. 2017;37:843–850PubMedCrossRef Staufer K, Roedl K, Kivaranovic D, et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int. 2017;37:843–850PubMedCrossRef
189.
go back to reference Wang PL, Silver SA, Djerboua M, et al. Recovery from dialysis-treated acute kidney injury in patients with cirrhosis: a population-based study. Am J Kidney Dis. 2022;80:55-64.e1PubMedCrossRef Wang PL, Silver SA, Djerboua M, et al. Recovery from dialysis-treated acute kidney injury in patients with cirrhosis: a population-based study. Am J Kidney Dis. 2022;80:55-64.e1PubMedCrossRef
190.
go back to reference Del Risco-Zevallos J, Andújar AM, Piñeiro G, et al. Management of acute renal replacement therapy in critically ill cirrhotic patients. Clin Kidney J. 2022;28(15):1060–1070 Del Risco-Zevallos J, Andújar AM, Piñeiro G, et al. Management of acute renal replacement therapy in critically ill cirrhotic patients. Clin Kidney J. 2022;28(15):1060–1070
191.
go back to reference Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol. 2018;13:16–25PubMedCrossRef Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol. 2018;13:16–25PubMedCrossRef
192.
go back to reference Zhang S, Suen SC, Gong CL, et al. Early transplantation maximizes survival in severe acute-on-chronic liver failure: results of a Markov decision process model. JHEP Rep. 2021;23(3): 100367CrossRef Zhang S, Suen SC, Gong CL, et al. Early transplantation maximizes survival in severe acute-on-chronic liver failure: results of a Markov decision process model. JHEP Rep. 2021;23(3): 100367CrossRef
193.
194.
go back to reference Artru F, Louvet A, Ruiz I, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–715PubMedCrossRef Artru F, Louvet A, Ruiz I, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–715PubMedCrossRef
195.
go back to reference Belli LS, Duvoux C, Artzner T, et al. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021;75:610–622PubMedCrossRef Belli LS, Duvoux C, Artzner T, et al. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021;75:610–622PubMedCrossRef
196.
go back to reference Choudhury A, Vijayaraghavan R, Maiwall R, APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party, et al. ‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. Hepatol Int. 2021;15:1376–1388PubMedCrossRef Choudhury A, Vijayaraghavan R, Maiwall R, APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party, et al. ‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. Hepatol Int. 2021;15:1376–1388PubMedCrossRef
197.
go back to reference Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156:1381-1391.e3PubMedCrossRef Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156:1381-1391.e3PubMedCrossRef
198.
go back to reference Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol. 2020;72:481–488PubMedCrossRef Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol. 2020;72:481–488PubMedCrossRef
199.
go back to reference Gustot T, Fernandez J, Garcia E, NONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252PubMedCrossRef Gustot T, Fernandez J, Garcia E, NONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252PubMedCrossRef
200.
go back to reference Asrani SK, Saracino G, O’Leary JG, et al. Recipient characteristics and morbidity and mortality after liver transplantation. J Hepatol. 2018;69:43–50PubMedCrossRef Asrani SK, Saracino G, O’Leary JG, et al. Recipient characteristics and morbidity and mortality after liver transplantation. J Hepatol. 2018;69:43–50PubMedCrossRef
201.
go back to reference Nadim MK, Genyk YS, Tokin C, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539–548PubMedCrossRef Nadim MK, Genyk YS, Tokin C, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539–548PubMedCrossRef
202.
go back to reference Agbim U, Sharma A, Maliakkal B, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF Consortium definition: a single-center study. Transplant Direct. 2020;18(6): e544CrossRef Agbim U, Sharma A, Maliakkal B, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF Consortium definition: a single-center study. Transplant Direct. 2020;18(6): e544CrossRef
203.
go back to reference Goosmann L, Buchholz A, Bangert K, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41:574–584PubMedCrossRef Goosmann L, Buchholz A, Bangert K, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41:574–584PubMedCrossRef
204.
go back to reference Putignano A, Gustot T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. Liver Transpl. 2017;23:234–243PubMedCrossRef Putignano A, Gustot T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. Liver Transpl. 2017;23:234–243PubMedCrossRef
205.
go back to reference Napoleone L, Solé C, Juanola A, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: relationship with kidney and patients’ outcome. Hepatol Commun. 2022;6:2121–2221PubMedPubMedCentralCrossRef Napoleone L, Solé C, Juanola A, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: relationship with kidney and patients’ outcome. Hepatol Commun. 2022;6:2121–2221PubMedPubMedCentralCrossRef
Metadata
Title
APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure
Authors
Rakhi Maiwall
Satender Pal Singh
Paolo Angeli
Richard Moreau
Aleksander Krag
Virender Singh
Ashwani K. Singal
S. S. Tan
Puneet Puri
Mamun Mahtab
George Lau
Qin Ning
Manoj Kumar Sharma
P. N. Rao
Dharmesh Kapoor
Subhash Gupta
Ajay Duseja
Manav Wadhawan
Dinesh Jothimani
Sanjiv Saigal
Sunil Taneja
Akash Shukla
Pankaj Puri
Deepak Govil
Gaurav Pandey
Kaushal Madan
C. E. Eapen
Jaya Benjamin
Ashok Chowdhury
Shweta Singh
Vaishali Salao
Jin Mo Yang
Saeed Hamid
Shalimar
Sanjiv Jasuja
Anand V. Kulkarni
Madund A. Niriella
Harsh Vardhan Tevethia
Vinod Arora
R. P. Mathur
Akash Roy
Ankur Jindal
Neeraj Saraf
Nipun Verma
Arka De
Narendra S. Choudhary
Rohit Mehtani
Phool Chand
Omkar Rudra
Shiv Kumar Sarin
Publication date
05-04-2024
Publisher
Springer India
Published in
Hepatology International
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-024-10650-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.